Theravance Biopharma, Inc.

NASDAQ:TBPH

Biotechnology

Healthcare
$17.03 -0.42%

-$0.07 today

Market cap
$882.64M
Beta
0.18
P/E (TTM)
7.4
EPS (TTM)
$2.23
52W Low $10.44High $21.03

Volume 10.02M

Average 0.43M

Balance Sheet

Inspect the capital base behind the business.

Assets

$485.57M

FY 2025 · Annual

+37.1% YoY

Liabilities

$188.85M

FY 2025 · Annual

+5.7% YoY

Equity

$296.72M

FY 2025 · Annual

+69.0% YoY

Balance Sheet

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Cash & Equivalents89.96M298.17M39.55M37.8M167.81M
Short-term Investments83.51M29.31M62.88M50.55M147.55M
Net Receivables57.6M16.79M17.47M68.44M95.54M
Inventory00000
Other Current Assets8.56M7.68M11.6M4.2M7.56M
Total Current Assets249.87M353.46M133.54M161.07M418.46M
Property, Plant & Equipment (Net)53.35M52M45.36M35.77M30.27M
Goodwill00000
Intangible Assets00000
Long-term Investments68.37M00014.35M
Tax Assets00000
Other Non-current Assets3.23M201.94M203.1M157.32M22.5M
Total Non-current Assets124.95M253.94M248.46M193.09M67.11M
Total Assets374.82M607.4M382M354.16M485.57M
Account Payables3.1M1.55M1.52M2.24M2.57M
Short-term Debt17.44M00010.95M
Tax Payables0005.85M0
Deferred Revenue98K24K000
Other Current Liabilities25.15M(24K)12.88M06.91M
Total Current Liabilities58.59M28.72M24.77M32.09M38.3M
Long-term Debt599.39M00032.8M
Deferred Tax Liabilities240K00085.68M
Deferred Revenue (Non-current)310K192K000
Other Non-current Liabilities2.18M91.29M99M107.42M313K
Total Non-current Liabilities654.81M136.89M144.24M146.53M150.55M
Total Liabilities713.39M165.6M169M178.62M188.85M
Common Stock1K1K001K
Retained Earnings(1.73B)(853.91M)(909.1M)(965.52M)(859.63M)
Accumulated OCI(0)(15K)(65K)7K61K
Other Stockholders Equity00(0)(0)0
Minority Interest00000
Total Equity(338.57M)441.8M213M175.55M296.72M
Total Debt669.52M52.16M49.16M49.82M75.5M
Net Debt579.56M(246.01M)9.61M12.02M(92.31M)

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$288.1M
Short-term Investments$106.6M
Receivables$15.6M
Other Current$7.4M
Total Current Assets$417.6M
PP&E (Net)$28.5M
Long-term Investments$836.0K
Other Non-current$25.3M
Total Non-current Assets$54.7M
Total Assets$472.3M

Analysis

Selected assets total $472.3M for Latest. The largest visible component is Cash & Equivalents at $288.1M, about 61.0% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13D/ASC 13D/A filingSep 25, 2026
4Statement of changes in beneficial ownershipSep 24, 2026
S-8 POSS-8 POS filingSep 24, 2026
4Statement of changes in beneficial ownershipSep 24, 2026
4Statement of changes in beneficial ownershipSep 24, 2026

How much cash does TBPH have?

Theravance Biopharma, Inc. (TBPH) reported $167.81M in cash and equivalents in fiscal 2025.

How much debt does TBPH carry?

Theravance Biopharma, Inc. (TBPH) reported $75.50M of total debt, with net debt of -$92.31M.